**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Library of Medicine; Cancellation of Meeting**

Notice is hereby given of the cancellation of the National Library of Medicine Board of Scientific Counselors, April 27, 2023, 11 a.m. to 5 p.m., Virtual Meeting, which was published in the Federal Register on October 6, 2022, 87 FR 193, Page Number 60696.

This notice is amended to announce that the meeting is cancelled and will not be rescheduled.


Miguelina Perez, Program Analyst, Office of Federal Advisory Committee Policy.

BILING CODE 4140–01–P

**Supplementary Information:**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Institute on Aging; Amended Notice of Meeting**

Notice is hereby given of a change in the meeting of the National Advisory Council on Aging, May 16, 2023, 02:00 p.m. to May 17, 2023, 02:30 p.m., National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Bethesda, MD 20892 which was published in the Federal Register on December 28, 2022, 321142.

The meeting notice is amended to change the start time of the meeting from 10:00 a.m., to 9:00 a.m. on the second day May 17, 2023. The end time will also change from 2:30 p.m. to 1:30 p.m. on May 17, 2023. The meeting is Partially Closed to the public.


Miguelina Perez, Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023–07161 Filed 4–5–23; 8:45 am]

BILING CODE 4140–01–P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Prospective Grant of an Exclusive Patent License: Manufacture, Distribution, Sale and Use of T-Cell-Based Immunotherapies for Solid Tumors**

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Cancer Institute, both institutes of the National Institutes of Health, Department of Health and Human Services, are contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to EnZeta Inc. of the State of Delaware.

**DATES:** Only written comments and/or applications for a license which are received by the National Cancer Institute’s Technology Transfer Center on or before April 21, 2023 will be considered.

**ADDRESSES:** Requests for copies of the patent applications, inquiries, and comments relating to the contemplated Exclusive Patent License should be directed to: Richard T. Girards, Jr., Esq., MBA, Senior Technology Transfer Manager, National Institutes of Health, NCI Technology Transfer Center by email (richard.girards@nih.gov) or phone (240–276–6825).

**SUPPLEMENTARY INFORMATION:**

**Intellectual Property**

**E–010–2021: Enhanced Antigen Reactivity of Immune Cells Expressing a Mutant Non–Signaling CD3 Zeta Chain**


3. any and all other U.S. and ex-U.S. patents and patent applications claiming priority to any one of the foregoing, now or in the future.

The patent and patent application rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America.

The prospective exclusive license territory may be worldwide and the fields of use may be limited to the following: manufacture, distribution, sale and use of T-cell-based immunotherapies for solid tumors.

These technologies disclose, e.g., cells expressing a modified CD3 subunit chain comprising at least one ITAM deletion. The inventive cells and populations thereof can be formulated into a composition, such as a pharmaceutical composition. Such cells and compositions thereof can be utilized to treat a wide variety of conditions, including but not limited to the indications within the scope of the contemplated exclusive license.

This Notice is made in accordance with 35 U.S.C. 209 and 37 CFR 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published Notice, the National Cancer Institute receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.

In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available.

License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information from these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552.
DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Fiscal Year (FY) 2023 Notice of Supplemental Funding Opportunity

AGENCY: Substance Abuse and Mental Health Services Administration, Department of Health and Human Services (HHS).

ACTION: Notice of intent to award supplemental funding.

SUMMARY: This notice is to inform the public that the Substance Abuse and Mental Health Services Administration (SAMHSA) is supporting administrative supplements in scope of the parent award for the 11 eligible grant recipients funded in FY 2017, under the Addiction Technology Transfer Centers (ATTC) Cooperative Agreements, Notice of Funding Opportunity (NOFO) TI–17–005. Recipients may receive up to $743,757 each, for a total of $8,181,327. These recipients have a current project end date of September 29, 2023. The supplemental funding will extend the project period by one-year and will continue training and technical assistance for providers who are serving patients with substance use disorder by improving their capacity and understanding of evidence-based practices, especially practices that are effective in combating substance misuse, including the opioid crisis.

FOR FURTHER INFORMATION CONTACT: Twyla Adams, Senior Public Health Advisor, Substance Abuse and Mental Health Services Administration, 5600 Fishers Lane, Rockville, MD 20857, telephone: 240–276–1835; email: Twyla.Adams@samhsa.hhs.gov.

SUPPLEMENTARY INFORMATION:

Funding Opportunity Title: FY 2017 Addiction Technology Transfer Centers Cooperative Agreements NOFO TI–17–005.

Assistance Listing Number: 93.243.

Authority: Section 509 of the Public Health Service Act, as amended.

Justification: Eligibility for this supplemental funding is limited to the 10 ATTC Regional Centers and ATTC National Coordinating Office funded in FY 2017, under the ATTC Cooperative Agreements funding announcement TI–17–005, as they are currently providing nationally- and regionally-focused treatment and recovery training activities, which will continue to be funded through this supplement.

This is not a formal request for application. Assistance will only be provided to the 10 ATTC Regional Centers and ATTC National Coordinating Office recipients based on the receipt of a satisfactory application and associated budget that is approved by a review group.


Carlos Castillo,
EC SB Acting Branch Chief, SAMHSA.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Fiscal Year (FY) 2023 Notice of Supplemental Funding Opportunity

AGENCY: Substance Abuse and Mental Health Services Administration, Department of Health and Human Services (HHS).

ACTION: Notice of intent to award supplemental funding.

SUMMARY: This notice is to inform the public that the Substance Abuse and Mental Health Services Administration (SAMHSA) is supporting administrative supplements in scope of the parent award for the 11 eligible grant recipients funded in FY 2019 under the Prevention Technology Transfer Centers (PTTCs) Cooperative Agreements, Notice of Funding Opportunity (NOFO) SP–19–001. The PTTC National Coordinating Center may receive up to $493,966 and the 10 PTTC Regional Centers may receive up to $600,000 each for a total of $6,492,160. These recipients have a current project end date of September 29, 2023. The supplemental funding will extend the project period by one-year and will continue providing training and technical assistance services and quality improvement activities to the substance abuse prevention workforce including professionals and pre-professionals, organizations, and others in the prevention community.

FOR FURTHER INFORMATION CONTACT: Thia Walker, DrPH., Public Health Advisor, Substance Abuse and Mental Health Services Administration, 5600 Fishers Lane, Rockville, MD 20857, telephone 240–276–1835; email: Thia.Walker@samhsa.hhs.gov.

SUPPLEMENTARY INFORMATION:

Funding Opportunity Title: FY 2019 Prevention Technology Transfer Centers Cooperative Agreements SP–19–001.

Assistance Listing Number: 93.243.

Authority: Section 509 of the Public Health Service Act, as amended.

Justification: Eligibility for this supplemental funding is limited to the 10 PTTC Regional Centers and PTTC National Coordinating Office funded under the PTTC Cooperative Agreements funding announcement SP–19–001, as they are currently providing nationally- and regionally-focused training and technical assistance services and quality improvement activities to the substance abuse prevention workforce including professionals and pre-professionals, organizations, and others in the prevention community, which will continue to be funded through this supplement.

This is not a formal request for application. Assistance will only be provided to the 10 PTTC Regional Centers and PTTC National Coordinating Center recipients based on the receipt of a satisfactory application and associated budget that is approved by a review group.


Carlos Castillo,
EC SB Acting Branch Chief, SAMHSA.